Drug intelligence / Profile preview

adebrelimab + SHR-1826 + SHR-8068

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Adebrelimab + SHR-1826 + SHR-8068 is an investigational triplet immunotherapy combination being developed by Jiangsu Hengrui Pharmaceuticals and its subsidiary Suzhou Suncadia Biopharmaceuticals. The regimen consists of three monoclonal antibodies: adebrelizumab (SHR-1316), an anti-PD-L1 antibody; SHR-1826, an anti-CD47 antibody; and SHR-8068, an anti-CTLA-4 antibody. This combination is designed to simultaneously target multiple immune evasion mechanisms by blocking the PD-1/PD-L1 and CTLA-4 checkpoints while also inhibiting the CD47 "don't eat me" signal, thereby enhancing T-cell and macrophage-mediated anti-tumor responses. It is currently being evaluated in Phase II clinical trials as a perioperative treatment for patients with resectable non-small cell lung cancer (NSCLC).

Other names: Adebrelimab Injection + SHR-1826 Injection + SHR-8068 Injection

Targets

CD47 (Cluster of Differentiation 47)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on adebrelimab + SHR-1826 + SHR-8068.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adebrelimab + SHR-1826 + SHR-8068.

Explore the full profile